EU External Trade - Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, Loprazolam (INN), mecloqualone (INN), methaqualone (INN) and zipeprol (INN); salts thereof

Extra-EU sourcing of Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, Loprazolam (INN), mecloqualone (INN), methaqualone (INN) and zipeprol (INN); salts thereof is highly concentrated. 🇨🇦 Canada captures 81.4% of imports (€9K), followed by 🇺🇸 United States (9.1%). With an HHI of 6757, this Concentrated market exposes the EU to supply dependency risks.

European exports of Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, Loprazolam (INN), mecloqualone (INN), methaqualone (INN) and zipeprol (INN); salts thereof are concentrated on a few markets. 🇪🇬 Egypt accounts for 46.9% (€44K), ahead of 🇦🇩 Andorra (31.4%). The top three destinations are 🇪🇬 Egypt, 🇦🇩 Andorra, 🇳🇴 Norway.

Within the EU, the leading importers of Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, Loprazolam (INN), mecloqualone (INN), methaqualone (INN) and zipeprol (INN); salts thereof are 🇩🇪 Germany, 🇵🇱 Poland, 🇫🇷 France. 🇩🇪 Germany accounts for 40.0% of EU imports.

In 2025, trade flows diverged: imports were surging (367.9%) while exports were falling sharply (-78.3%), signalling a structural market shift.